New cocktail of drugs aims to wipe out aggressive breast cancer before surgery

NCT ID NCT07187674

Not yet recruiting Disease control Sponsor: Harbin Medical University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (olaparib), and chemotherapy (paclitaxel) given before surgery to 20 women with early, high-risk triple negative breast cancer that has a specific DNA repair defect (HRD positive). The goal is to see if this approach can eliminate all cancer cells in the breast and lymph nodes by the time of surgery. The study is exploratory and will also monitor safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: iparomlimab, tuvonralimab, olaparib, and paclitaxel
What this could lead to: If successful, this could point toward a more effective pre-surgery treatment for a hard-to-treat breast cancer type, potentially improving the chance of no cancer remaining after surgery.
What could go wrong: This is a very early, small study with only 20 participants, so results may not apply broadly. The combination of drugs may cause significant side effects, and it is not yet known if it works better than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER (TNBC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE-NEGATIVE BREAST CANCER (TNBC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.